Logo

CNTX

Context Therapeutics Inc.

CNTX

Context Therapeutics Inc. • NASDAQ
$1.12 ▼ -0.88% (-0.01)
Market Cap $102.90 M
52w High $1.65
52w Low $0.49
Dividend Yield 0%
P/E -4.67
Volume 53.75K
Outstanding Shares 91.88M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $10.606M ▲ $-9.693M ▼ 0% $-0.1 ▼ $-9.689M ▲
Q2-2025 $0 $9.758M ▲ $-8.828M ▼ 0% $-0.093 ▼ $-9.754M ▼
Q1-2025 $0 $5.529M ▲ $-4.577M ▼ 0% $-0.05 ▲ $-5.525M ▼
Q4-2024 $0 $4.31M ▼ $-3.343M ▲ 0% $-0.057 ▲ $-4.307M ▲
Q3-2024 $0 $18.701M $-17.46M 0% $-0.22 $-18.699M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $76.938M ▼ $79.231M ▼ $6.057M ▲ $73.174M ▼
Q2-2025 $83.517M ▼ $87.152M ▼ $4.608M ▲ $82.544M ▼
Q1-2025 $89.352M ▼ $92.965M ▼ $1.983M ▼ $90.983M ▼
Q4-2024 $94.43M ▲ $98.127M ▲ $2.86M ▲ $95.266M ▲
Q3-2024 $84.802M $86.33M $2.472M $83.858M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-9.693M ▼ $-6.579M ▼ $0 $0 $-6.579M ▼ $-6.579M ▼
Q2-2025 $-8.828M ▼ $-5.835M ▼ $0 ▲ $0 ▲ $-5.835M ▼ $-5.835M ▼
Q1-2025 $-4.577M ▼ $-5.028M ▼ $-33.948K ▼ $-15.268K ▼ $-5.078M ▼ $-5.062M ▼
Q4-2024 $-3.343M ▲ $-4.907M ▼ $0 ▲ $14.535M ▲ $9.628M ▲ $-4.907M ▼
Q3-2024 $-17.46M $-1.933M $-14.757M $-44.632K $-16.734M $-1.941M

Five-Year Company Overview

Income Statement

Income Statement Context Therapeutics is still a pure R&D biotech story, with no product revenue yet across the past several years. Its income statement reflects this: expenses are primarily research and corporate overhead, leading to steady but relatively modest operating losses. Net losses have been consistent, indicating the company is spending to advance its oncology pipeline but has not yet reached any commercial stage. Per‑share results have moved around more than the underlying loss level, suggesting share count changes rather than big shifts in the underlying cost structure. Overall, it looks like a lean, early-stage biotech focused on controlled spending while it develops its science.

Balance Sheet

Balance Sheet The balance sheet is simple and very small in scale. Assets are largely cash, with little in the way of physical assets or long-term investments, which is common for a clinical-stage biotech. Equity is positive but thin, reflecting limited historical funding and ongoing losses. There is essentially no meaningful financial debt at present, which reduces balance sheet risk but also highlights that the main constraint is future access to capital, not leverage. In short, the company is lightly capitalized, relatively clean from a debt standpoint, and highly dependent on periodic financing to sustain operations.

Cash Flow

Cash Flow Cash flows show a consistent pattern of cash being used rather than generated, driven by operating expenses tied to research, clinical work, and overhead. The cash burn appears modest in absolute terms, but there is still a steady outflow year after year. Capital spending is minimal, which fits a biotech model built more on people and intellectual property than on heavy equipment. Free cash flow is negative, so the company relies on past or future financing transactions to fund its pipeline. The key question going forward will be how long the current cash can support operations and when new funding might be needed, especially as trials expand.

Competitive Edge

Competitive Edge Context is trying to secure a niche in a crowded oncology field by specializing in next-generation T‑cell engagers for solid tumors, an area where many others have struggled. Its edge is not scale, but specialization: sophisticated antibody engineering aimed at making treatments more precise and less toxic. By focusing on challenging but well-known tumor targets like Claudin 6, mesothelin, and Nectin‑4, the company is positioning itself as a problem-solver for issues that have tripped up prior approaches, such as off‑tumor toxicity and shed antigens. However, it operates in a space dominated by much larger pharma and biotech players with deeper pockets, broader pipelines, and established commercial footprints. That makes partnerships, data quality, and clear differentiation especially important for its long-term positioning.

Innovation and R&D

Innovation and R&D Innovation is the clear centerpiece of Context’s story. Its pipeline is built around engineered bispecific antibodies that try to improve both safety and effectiveness in solid tumors. One program uses very high selectivity to target a tumor-specific protein with minimal impact on healthy tissues. Another addresses the common problem of “shed” tumor antigens that can soak up drug in the bloodstream, by tuning how strongly the antibody binds when it encounters clustered targets on cancer cells. A third candidate uses pH‑sensitive binding designed to stay relatively inactive in normal tissue and become active only in the more acidic tumor environment. Together, these approaches show a sophisticated R&D engine focused on solving known technical hurdles in immuno‑oncology. The main uncertainty is classic for early-stage biotech: all key assets are pre‑commercial, with just early clinical testing underway, so real-world safety and efficacy data over the next few years will be decisive.

Summary

Context Therapeutics is a very early-stage, oncology-focused biotech with no current product revenue and a small but focused cost base. Financially, it runs lean, with modest recurring losses, a cash‑heavy and debt‑light balance sheet, and a predictable pattern of negative cash flow tied to R&D. Strategically, its value proposition rests on innovative antibody engineering designed to tackle some of the toughest problems in solid tumor immunotherapy. The opportunity is tied to the potential of its T‑cell engager platform and upcoming trial readouts; the risks center on clinical success, regulatory outcomes, and maintaining access to capital as development progresses. For observers, this is primarily a science-and-clinical-milestones story rather than a traditional earnings or cash-generation story at this stage.

NEWS

November 7, 2025 · 7:30 AM UTC

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Read more

November 5, 2025 · 4:15 PM UTC

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

Read more

October 28, 2025 · 8:00 AM UTC

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

Read more

October 28, 2025 · 7:30 AM UTC

Context Therapeutics to Participate in Upcoming Investor Conferences

Read more

October 6, 2025 · 7:30 AM UTC

Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Read more